CGON Other Current Assets vs Current Deferred Revenue Analysis
| CGON Stock | 34.75 0.65 1.91% |
CG Oncology, financial indicator trend analysis is way more than just evaluating CG Oncology, Common prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether CG Oncology, Common is a good investment. Please check the relationship between CG Oncology, Other Current Assets and its Current Deferred Revenue accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CG Oncology, Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.
Other Current Assets vs Current Deferred Revenue
Other Current Assets vs Current Deferred Revenue Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of CG Oncology, Common Other Current Assets account and Current Deferred Revenue. At this time, the significance of the direction appears to have strong contrarian relationship.
The correlation between CG Oncology,'s Other Current Assets and Current Deferred Revenue is -0.56. Overlapping area represents the amount of variation of Other Current Assets that can explain the historical movement of Current Deferred Revenue in the same time period over historical financial statements of CG Oncology, Common, assuming nothing else is changed. The correlation between historical values of CG Oncology,'s Other Current Assets and Current Deferred Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Other Current Assets of CG Oncology, Common are associated (or correlated) with its Current Deferred Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Current Deferred Revenue has no effect on the direction of Other Current Assets i.e., CG Oncology,'s Other Current Assets and Current Deferred Revenue go up and down completely randomly.
Correlation Coefficient | -0.56 |
| Relationship Direction | Negative |
| Relationship Strength | Very Weak |
Other Current Assets
Assets expected to be converted into cash, sold, or consumed either in one year or in the operating cycle, which are not included under standard current asset categories.Current Deferred Revenue
Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.Most indicators from CG Oncology,'s fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into CG Oncology, Common current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CG Oncology, Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. As of the 30th of November 2024, Sales General And Administrative To Revenue is likely to grow to 50.96, while Selling General Administrative is likely to drop about 7.7 M.
| 2010 | 2022 | 2023 | 2024 (projected) | Interest Expense | 451K | 1K | 6.9M | 7.2M | Depreciation And Amortization | 10K | 15K | 17K | 15.4K |
CG Oncology, fundamental ratios Correlations
Click cells to compare fundamentals
CG Oncology, Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Pair Trading with CG Oncology,
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if CG Oncology, position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in CG Oncology, will appreciate offsetting losses from the drop in the long position's value.Moving against CGON Stock
| 0.45 | BMY | Bristol Myers Squibb Sell-off Trend | PairCorr |
| 0.43 | ESPR | Esperion Therapeutics Buyout Trend | PairCorr |
| 0.39 | VTRS | Viatris | PairCorr |
| 0.32 | BFRIW | Biofrontera Warrants | PairCorr |
The ability to find closely correlated positions to CG Oncology, could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace CG Oncology, when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back CG Oncology, - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling CG Oncology, Common to buy it.
The correlation of CG Oncology, is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as CG Oncology, moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if CG Oncology, Common moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for CG Oncology, can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CG Oncology, Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CG Oncology,. If investors know CGON will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CG Oncology, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (15.87) | Revenue Per Share 0.015 | Quarterly Revenue Growth 3.778 | Return On Assets (0.16) | Return On Equity (0.20) |
The market value of CG Oncology, Common is measured differently than its book value, which is the value of CGON that is recorded on the company's balance sheet. Investors also form their own opinion of CG Oncology,'s value that differs from its market value or its book value, called intrinsic value, which is CG Oncology,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CG Oncology,'s market value can be influenced by many factors that don't directly affect CG Oncology,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CG Oncology,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if CG Oncology, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CG Oncology,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.